Bank Clariden Leu
2
36M
2
2
- Areas of investment
Summary
The usual cause for the fund is to invest in rounds with 7 partakers. Despite the Bank Clariden Leu, startups are often financed by U.S. Venture Partners (USVP), Nomura International, Cystic Fibrosis Foundation. The meaningful sponsors for the fund in investment in the same round are Warburg Pincus, U.S. Venture Partners (USVP), Phase4 Ventures. In the next rounds fund is usually obtained by QVT Financial, Horizon Technology Finance.
Among the most successful fund investment fields, there are Information Technology, Biotechnology. Besides, a startup needs to be aged 11-15 years to get the investment from the fund. The fund has exact preference in a number of founders of portfolio startups. Among the most popular portfolio startups of the fund, we may highlight Palatin Technologies, Altus Pharmaceuticals.
The top activity for fund was in 2004. Deals in the range of 10 - 50 millions dollars are the general things for fund. The increased amount of exits for fund were in 2006. The fund is generally included in less than 2 deals every year. The average startup value when the investment from Bank Clariden Leu is 50-100 millions dollars.
Investments analytics
Analytics
- Total investments
- 2
- Lead investments
- 0
- Exits
- 2
- Investments by industry
- Data Center (1)
- Consulting (1)
- Information Technology (1)
- Pharmaceutical (1)
- Biotechnology (1) Show 2 more
- Investments by region
-
- United States (2)
- Peak activity year
- 2004
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 30
- Avg. valuation at time of investment
- 157M
- Group Appearance index
- 1.00
- Avg. company exit year
- 10
- Avg. multiplicator
- 2.48
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| Altus Pharmaceuticals | 26 May 2004 | Information Technology, Pharmaceutical, Data Center, Consulting | Late Stage Venture | 51M | United States, Ohio, Independence |
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.